India Pharma Outlook Team | Wednesday, 13 August 2025
Cohance Lifesciences Limited, the partner of choice for global innovative pharma companies, announces Rs. 23 crore investments and good progress on construction of its new cGMP oligonucleotide building block manufacturing facility located in Hyderabad, India.
This investment not only bolsters Cohance's integrated oligonucleotide platform but also further enhances its partner of choice for emerging modalities and manufacturing facility. Cohance continues to leverage its deep expertise of modified nucleosides and locked nucleic acids (LNA) and has a history of successful delivery of complex nucleoside and nucleic acid synthesis at the R&D level.
The new facility will give the Company the capability to commercialise these high-value chemistries from laboratory scale to full commercial scale manufacturing which is key to assisting innovators develop and advance oligonucleotide-based therapeutics.
The facility will add fit-for-purpose GMP capacity of up to 700 kg yearly, with potential for future expansion, and will be integrated with a pilot plant for early-stage synthesis and non-GMP scale-up. This scale is intended to satisfy the exacting specifications of complicated oligonucleotide building block synthesis, in conjunction with sophisticated environmental controls such as ISO Class 8 clean rooms and RH-controlled regions.
Audits are scheduled for the upcoming quarters, and customer engagements are currently in progress. Modified nucleotides and kilo lab validations are underway, and GMP-grade PMO and LNA amidite validations are anticipated to start in CY26.
Also Read: Amgen to Invest $200M in AI-Driven Innovation Hub in India
Vivek Sharma, Executive Chairman, Cohance Lifesciences, said: "Oligonucleotides are a fast-emerging therapeutic class, and innovators are seeking integrated, cost-efficient partners with scalable GMP capacity. This facility is a high-impact strategic investment with modern technologies that complements our pilot and scale-up assets, positioning Cohance to deliver with speed, quality, and flexibility while expanding our role in next-generation therapeutics."
